Table 3

- Investigations and hospital course.

Investigations	n (%)
Diagnosis
Blood culture	6 (9.1)
Drainage fluid culture	3 (4.5)
Tracheal aspirate	51 (77.3)
Urine culture	3 (4.5)
Vascular tip culture	1 (1.5)
Wound culture	2 (3.0)
Polymicrobial infection at the time of the episode^*	42 (63.6)
Bacteria	40 (95.2)
Fungus	12 (28.6)
Lab results
Leukopenia	19 (19.8)
Anemia	54 (81.8)
Thrombocytopenia	32 (48.5)
Neutropenia	3 (4.5)
Procalcitonin levels (>0.25 ng/mL)	35 (53.53)
C-reactive protein levels (>50 mg/L)	18 (27.3)
Received target antimicrobial treatment	43 (65.2)
Monotherapy	35 (81.4)^{^†}
Trimethoprim/sulfamethoxazole	10 (23.3)^{^†}
Ciprofloxacin	20 (46.5)^{^†}
Levofloxacin	2 (4.7)^{^†}
Meropenem	1 (2.3)^{^†}
Imipenem	2 (4.7)^{^†}
Combination therapy	8 (18.6)^{^†}
Trimethoprim/sulfamethoxazole + levofloxacin	2 (4.7)^{^†}
Trimethoprim/sulfamethoxazole + ciprofloxacin	4 (9.3)^{^†}
Trimethoprim/sulfamethoxazole + tigecycline	1 (2.3)^{^†}
Gentamycin + trimethoprim/sulfamethoxazole + levofloxacin + minocycline	1 (2.3)^†
Antimicrobial treatment period (days) (n=43)	20 (14-29)
Outcome
Recovered	39 (59.1)
Died	23 (34.8)
Relapsed (while on treatment)	2 (3.0)
Recurrence (within one month)	2 (3.0)
Days from the episode to death (n=23)	17 (5-41)
28-day mortality	15 (22.7)

Values are presented as numbers and percentages (%) or median and interquartile range (IQR).
↵* A total of 10 patients had both bacteria and fungi.
↵^† Percentages were calculated using 43 (number of patients who were on treatment) as a denominator.